Clinical Trials

182 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07445048 2026-04-17

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

370 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07457528 2026-03-11

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

46 enrolled

Esophageal Squamous Cell Carcinoma

NCT04821778 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

2,000 enrolled

Esophageal Neoplasms

NCT04821843 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

2,000 enrolled

Esophageal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT07333274 2026-01-12

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

335 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06770452 2025-09-23

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

32 enrolled

Pancreatic Neoplasms

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

30 enrolled

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06988956 2025-05-25

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

95 enrolled

Esophageal Squamous Cell Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

70 enrolled

Nasopharyngeal Carcinoma

NCT06722911 2024-12-09

Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer

57 enrolled

Pancreatic Cancer Resectable

NCT06718205 2024-12-05

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

112 enrolled

Esophageal Neoplasms

NCT06389760 2024-10-31

Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

57 enrolled

Pancreatic Neoplasms

NCT06429839 2024-05-28

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

55 enrolled

Esophageal Neoplasms

NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

30 enrolled

HCC

NCT06410651 2024-05-13

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

53 enrolled

Esophageal Neoplasms

NCT06404840 2024-05-08

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

30 enrolled

Pancreatic Neoplasms

NCT06259721 2024-03-07

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

22 enrolled

Nasopharyngeal Carcinoma

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

228 enrolled

Nasopharyngeal Carcinoma

NCT05772208 2023-03-16

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

459 enrolled

Nasopharyngeal Carcinoma

NCT05717790 2023-02-08

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Phase NA Recruiting

288 enrolled